Want to see BCYC full AI Analyst Report?
Top Page
Bicycle Therapeutics
(NASDAQ:BCYC)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.00
▲(3.36% Upside)
Action:Reiterated
Date:07/30/26
The score is held back primarily by weak financial performance (persistent losses and cash burn despite a low-debt balance sheet) and bearish technical positioning (trading below all major moving averages with high volatility). Positive Phase 2 clinical data provides an offsetting catalyst, but valuation support is limited given the company remains unprofitable and offers no dividend yield.
Positive Factors
Low leverage and solid liquidity
A very low debt-to-equity ratio and substantial cash reduce refinancing and interest risks, giving management durable financial flexibility to fund clinical programs and partnerships over the next several quarters without immediate financing pressure. This supports execution of multi-stage development plans.
Negative Factors
High cash burn and negative cash flow
Sustained negative operating and free cash flow means the company will continue to draw on cash reserves to fund trials and operations. Even with strong liquidity today, prolonged burn increases financing dependency over time and can pressure strategic optionality if clinical timelines or costs extend.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and solid liquidity
A very low debt-to-equity ratio and substantial cash reduce refinancing and interest risks, giving management durable financial flexibility to fund clinical programs and partnerships over the next several quarters without immediate financing pressure. This supports execution of multi-stage development plans.
Read all positive factors
Bicycle Therapeutics (BCYC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$269.48M
Dividend YieldN/A
Average Volume (3M)527.73K
Price to Earnings (P/E)―
Beta (1Y)1.86
Revenue Growth215.59%
EPS Growth22.48%
CountryUS
Employees288
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.73
Shares Outstanding50,554,928
10 Day Avg. Volume274,075
30 Day Avg. Volume527,728
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)0.80
Price to Sales (P/S)6.76
P/FCF Ratio-1.94
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$9.80Price Target Upside153.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.32
Revenue Forecast (FY)$18.90M
Bicycle Therapeutics Business Overview & Revenue Model
Company Description
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's le...
How the Company Makes Money
Bicycle Therapeutics primarily makes money through (1) collaboration and license revenue and (2) other operating income typical of clinical-stage biopharmaceutical companies, such as funding associated with partnered R&D activities, where applicab...
Bicycle Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.20M | 72.59M | 35.27M | 26.98M | 14.46M | 11.70M |
| Gross Profit | 61.20M | 72.59M | -137.69M | -129.52M | 14.46M | 11.70M |
| EBITDA | -183.20M | -212.18M | -164.89M | -169.40M | -107.21M | -64.09M |
| Net Income | -190.41M | -218.96M | -169.03M | -180.66M | -112.72M | -66.82M |
Balance Sheet | ||||||
| Total Assets | 606.58M | 717.60M | 956.87M | 595.34M | 410.61M | 479.79M |
| Cash, Cash Equivalents and Short-Term Investments | 510.05M | 628.11M | 879.52M | 526.42M | 339.15M | 438.68M |
| Total Debt | 13.68M | 17.52M | 9.49M | 44.96M | 44.33M | 44.34M |
| Total Liabilities | 96.32M | 107.62M | 163.81M | 224.41M | 139.83M | 133.54M |
| Stockholders Equity | 510.25M | 609.98M | 793.06M | 370.93M | 270.78M | 346.25M |
Cash Flow | ||||||
| Free Cash Flow | -205.59M | -252.61M | -165.96M | -63.56M | -105.10M | -16.82M |
| Operating Cash Flow | -205.72M | -249.68M | -164.72M | -60.63M | -86.11M | -14.79M |
| Investing Cash Flow | -2.22M | -2.35M | -1.24M | -2.93M | -18.99M | -2.03M |
| Financing Cash Flow | -148.84K | -131.00K | 519.75M | 250.03M | 6.69M | 320.73M |
Bicycle Therapeutics Technical Analysis
Negative
3.87
Price Trends
4.18
Negative
4.48
Negative
5.56
Negative
Market Momentum
-0.09
Positive
42.86
Neutral
27.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCYC, the sentiment is Negative. The current price of 3.87 is below the 20-day moving average (MA) of 4.10, below the 50-day MA of 4.18, and below the 200-day MA of 5.56, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 42.86 is Neutral, neither overbought nor oversold. The STOCH value of 27.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCYC.
Bicycle Therapeutics Risk Analysis
Bicycle Therapeutics disclosed 75 risk factors in its most recent earnings report. Bicycle Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bicycle Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $1.27B | -908.41 | -5.68% | ― | 79.89% | 68.13% | |
62 Neutral | $1.78B | -9.75 | -35.89% | ― | ― | -63.41% | |
52 Neutral | $1.97B | -66.12 | 31.23% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $269.48M | -1.41 | -33.22% | ― | 215.59% | 22.48% | |
49 Neutral | $2.60B | -9.97 | -253.85% | ― | ― | -15.28% |
* Healthcare Sector Average
BCYC
Bicycle Therapeutics
3.94
-3.92
-49.87%
KOD
Kodiak Sciences
42.89
34.80
430.16%
ETON
Eton Pharmaceuticals
45.83
31.10
211.13%
NBTX
Nanobiotix
39.52
32.57
468.63%
BCAX
Bicara Therapeutics Inc.
26.10
14.74
129.75%
Bicycle Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Bicycle Therapeutics Shareholders Approve Proposals at 2026 AGM
Positive
Jun 18, 2026
Bicycle Therapeutics plc held its annual general meeting of shareholders on June 17, 2026, with approximately 98.64% of issued and outstanding ordinary shares represented. Shareholders re-elected directors Felix Baker and Hervé Hoppenot, appr...
Business Operations and Strategy
Bicycle Therapeutics Reports Positive Duravelo-2 Phase 2 Data
Positive
May 21, 2026
On May 21, 2026, Bicycle Therapeutics reported initial data from its Duravelo-2 randomized Phase 2 trial of zelenectide pevedotin in previously untreated metastatic urothelial cancer, showing response rates comparable to standard of care and a pot...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.